<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Expression of <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> E synthase (PGES) - an enzyme of the <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> biosynthetic pathway with suspected impact on <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>--was studied in Barrett's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> to determine its pathogenetic role and prognostic impact in this entity </plain></SENT>
<SENT sid="1" pm="."><plain>Expression analysis of PGES was performed on <z:chebi fb="2" ids="33699">mRNA</z:chebi> level (quantitative reverse transcription polymerase chain rection [RT-PCR]) in a large surgical series of 123 primary resected <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> of the distal esophagus (Barrett's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Gene expression results were correlated with clinical parameters, overall survival and expression levels of previously analyzed target genes of the cyclooxygenase (COX) pathway (COX-1, COX-2) and mediators of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> (vascular endothelial growth factor [VEGF]-A) and lymphangiogenesis [VEGF-C] </plain></SENT>
<SENT sid="3" pm="."><plain>Expression of PGES was demonstrated in <z:hpo ids='HP_0000001'>all</z:hpo> 123 tumors (100%) on <z:chebi fb="2" ids="33699">mRNA</z:chebi> level (quantitative RT-PCR) </plain></SENT>
<SENT sid="4" pm="."><plain>Relative <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels were highly variable between different cases </plain></SENT>
<SENT sid="5" pm="."><plain>Gene expression showed a strong positive correlation with both COX isoforms (COX-1: r = 0.502, P &lt; 0.001; COX-2: r = 0.679, P &lt; 0.001), with the angiogenetic VEGF-A (r = 0.583, P &lt; 0.001) and with the lymphangiogentic VEGF-C (r = 0.465, P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>PGES <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression showed no significant correlation with clinicopathologic parameters (i.e. pTNM categories, UICC stage, survival) </plain></SENT>
<SENT sid="7" pm="."><plain>Variable overexpression of PGES seems to be potentially implicated in Barrett's <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Gene expression of PGES is strongly correlated with other mediators of the <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> biosynthetic pathway, that is both COX isoforms (COX-1 and COX-2) </plain></SENT>
<SENT sid="9" pm="."><plain>However, no impact on patients' outcome in relation to PGES expression was found </plain></SENT>
</text></document>